The CLEOPATRA study demonstrated an additional improvement in survival outcomes in treatment-naïve (chemotherapy and biological therapy, one endocrine treatment was allowed) HER2-positive patients with metastatic BC. The gene discussed is ERBB2; the disease is breast cancer.